P cadherin (CDH3) Human shRNA Plasmid Kit (Locus ID 1001)
CAT#: TL314033
CDH3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 5,740.00
Cited in 1 publication. |
Product images
![](https://cdn.origene.com/img/defaults-img.jpg)
CNY 1,999.00
CNY 2,700.00
CNY 4,070.00
Specifications
Product Data | |
Product Name | P cadherin (CDH3) Human shRNA Plasmid Kit (Locus ID 1001) |
Locus ID | 1001 |
UniProt ID | P22223 |
Synonyms | CDHP; HJMD; PCAD |
Vector | pGFP-C-shLenti |
Format | Lentiviral plasmids |
Kit Components | CDH3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 1001). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free. |
RefSeq | NM_001317195, NM_001317196, NM_001793, NM_001793.1, NM_001793.2, NM_001793.4, NM_001793.5, BC041846, BC041846.1, BC014462, NM_001793.6 |
Summary | This gene encodes a classical cadherin of the cadherin superfamily. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed to generate the mature glycoprotein. This calcium-dependent cell-cell adhesion protein is comprised of five extracellular cadherin repeats, a transmembrane region and a highly conserved cytoplasmic tail. This gene is located in a gene cluster in a region on the long arm of chromosome 16 that is involved in loss of heterozygosity events in breast and prostate cancer. In addition, aberrant expression of this protein is observed in cervical adenocarcinomas. Mutations in this gene are associated with hypotrichosis with juvenile macular dystrophy and ectodermal dysplasia, ectrodactyly, and macular dystrophy syndrome (EEMS). [provided by RefSeq, Nov 2015] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (1)
The use of this RNAi has been cited in the following citations: |
---|
A Cdh3-β-catenin-laminin signaling axis in a subset of breast tumor leader cells control leader cell polarization and directional collective migration
,null,
Developmental cell
,PubMed ID 36626870
[CDH3]
|
Documents
Product Manuals |
FAQs |
SDS |